MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4⁺ T cells in vivo

Thomas V. Guya T cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia;b Pillai Labratory, Ragon Institute of MGH, Harvard and MIT, Boston, MA, USA

https://orcid.org/0009-0009-0383-4469 View further author information

Alexandra M. Terrya T cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia;c Genmab, Utrecht, The NetherlandsView further author information

Helen M. McGuirea T cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia;d School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, AustraliaView further author information

Elena Shklovskayaa T cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia;e Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, AustraliaView further author information

Barbara Fazekas de St Grotha T cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia;d School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, AustraliaCorrespondence[email protected]
View further author information

MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4⁺ T cells in vivo

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4+ T cells in vivo

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4⁺ T cells in vivo